on INVENTIVA (EPA:IVA)
Inventiva to Present at 2026 Jefferies Global Healthcare Conference
Inventiva, a clinical-stage biopharmaceutical company, has announced its participation in the 2026 Jefferies Global Healthcare Conference. The event is scheduled to take place from June 2-4, 2026, in New York City. CEO Andrew Obenshain will represent the company with a presentation on June 3, from 5:30-6:00 pm (ET). Additionally, Inventiva will conduct one-on-one meetings during the conference.
The company is recognized for its focus on developing oral therapies targeting metabolic dysfunction-associated steatohepatitis (MASH). As part of its core projects, Inventiva is working on lanifibranor, a pan-PPAR agonist, currently under a Phase 3 clinical trial named NATiV3.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INVENTIVA news